tiprankstipranks
Advertisement
Advertisement

GB:AZN Stock Latest News

Abivax re-engages Centerview amid renewed takeover interest, La Lettre says
The FlyAbivax re-engages Centerview amid renewed takeover interest, La Lettre says
4d ago
AZN
LLY
AstraZeneca’s New Saruparib Trial Targets Next Wave of Prostate Cancer Growth
PremiumCompany Announcements
AstraZeneca’s New Saruparib Trial Targets Next Wave of Prostate Cancer Growth
4d ago
AZN
AstraZeneca Backs New EGFR Lung Cancer Combo In Fresh Phase 2 Trial
PremiumCompany Announcements
AstraZeneca Backs New EGFR Lung Cancer Combo In Fresh Phase 2 Trial
4d ago
AZN
AstraZeneca price target lowered to 15,300 GBp at Morgan Stanley
PremiumThe Fly
AstraZeneca price target lowered to 15,300 GBp at Morgan Stanley
5d ago
AZN
AstraZeneca’s Eluminate-4 Trial Targets High-Risk Diabetes Patients, Raising Long-Term Upside for AZN
PremiumCompany Announcements
AstraZeneca’s Eluminate-4 Trial Targets High-Risk Diabetes Patients, Raising Long-Term Upside for AZN
6d ago
AZN
AstraZeneca’s Eluminate-5 Trial: A New Combo Bid in Type 2 Diabetes
PremiumCompany AnnouncementsAstraZeneca’s Eluminate-5 Trial: A New Combo Bid in Type 2 Diabetes
6d ago
AZN
AstraZeneca Advances Eluminate-1 Phase III Trial in Type 2 Diabetes
Premium
Company Announcements
AstraZeneca Advances Eluminate-1 Phase III Trial in Type 2 Diabetes
6d ago
AZN
AstraZeneca Completes Key Pediatric Asthma Inhaler Study, Setting Up Next Moves for Symbicort
Premium
Company Announcements
AstraZeneca Completes Key Pediatric Asthma Inhaler Study, Setting Up Next Moves for Symbicort
6d ago
AZN
After Crinetics’ $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story?
PremiumTipRanks Newswire
After Crinetics’ $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story?
6d ago
AZN
LLY
AstraZeneca’s Elecoglipron Takes On Semaglutide in Key Phase III Diabetes Trial
PremiumCompany Announcements
AstraZeneca’s Elecoglipron Takes On Semaglutide in Key Phase III Diabetes Trial
7d ago
AZN
AstraZeneca Advances AZD7760 Trial in Japan, Quietly Expanding Its Infection-Prevention Pipeline
PremiumCompany Announcements
AstraZeneca Advances AZD7760 Trial in Japan, Quietly Expanding Its Infection-Prevention Pipeline
7d ago
AZN
AstraZeneca Deepens NSCLC Precision Strategy With New MET Gene Profiling Study
PremiumCompany Announcements
AstraZeneca Deepens NSCLC Precision Strategy With New MET Gene Profiling Study
7d ago
AZN
AstraZeneca to acquire rights to develop, commercialize Zegfrovy for $600M
PremiumThe FlyAstraZeneca to acquire rights to develop, commercialize Zegfrovy for $600M
7d ago
AZN
AstraZeneca Buys Global Rights to Dizal’s Zegfrovy in $1.5bn Lung Cancer Deal
Premium
Company Announcements
AstraZeneca Buys Global Rights to Dizal’s Zegfrovy in $1.5bn Lung Cancer Deal
7d ago
AZN
AstraZeneca Advances AZD5004 Combo Data With Diabetes Drugs, Offering Subtle Upside for AZN Investors
Premium
Company Announcements
AstraZeneca Advances AZD5004 Combo Data With Diabetes Drugs, Offering Subtle Upside for AZN Investors
8d ago
AZN
Alnylam price target raised to $485 from $470 at H.C. Wainwright
PremiumThe Fly
Alnylam price target raised to $485 from $470 at H.C. Wainwright
8d ago
AZN
ALNY
AstraZeneca downgraded to Hold from Buy at HSBC
PremiumThe Fly
AstraZeneca downgraded to Hold from Buy at HSBC
8d ago
AZN
Federal health role nominee has record of vaccine skepticism, Stat News reports
PremiumThe Fly
Federal health role nominee has record of vaccine skepticism, Stat News reports
11d ago
AZN
EBS
SERAFA-1 Trial Update: AstraZeneca and Icon Deepen Their Breast Cancer Bet
PremiumCompany Announcements
SERAFA-1 Trial Update: AstraZeneca and Icon Deepen Their Breast Cancer Bet
11d ago
ICLR
AstraZeneca’s Embold Trial Signals a Big Push Into the Obesity Drug Race
PremiumCompany AnnouncementsAstraZeneca’s Embold Trial Signals a Big Push Into the Obesity Drug Race
11d ago
AZN
AstraZeneca price target lowered to 17,500 GBp from 18,000 GBp at Citi
Premium
The Fly
AstraZeneca price target lowered to 17,500 GBp from 18,000 GBp at Citi
11d ago
AZN
Intellia Therapeutics price target raised to $17 from $12 at Wedbush
Premium
The Fly
Intellia Therapeutics price target raised to $17 from $12 at Wedbush
11d ago
AZN
ALNY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >